Alpex Pharma is a pharmaceutical company active in Research & Development and Production of ODT (Orally Dispersible Tablet) called also “fast melt” and effervescent tablets. Alpex Pharma has developed a unique proprietary covering ODT technology.
The high production capacity and advanced R&D technologies makes Alpex Pharma to be one of the most important company of the world in the field of fast melt and effervescent tablets.
The company has a state-of-the-art manufacturing and R&D facilities of some 7000 square meters, with separate pharmaceutical and nutritional plant GMP compliant.
1988 The company started in 1988 under the name Aesculapius Pharma.
1992 In 1992 Aesculapius Pharma was acquired by Elan Corporation PLC and since the acquisition heavy investement have been made in R&D (fast melt technology) and manufacturing facility.
1998 The first fast melt nutritional product was commercialised in 1998.
2001 The first fast melt pharmaceutical product was commercialised in 2001.
2004 In 2004, the majority of capital shares of the company was aquired by funds managed by Sanders Morris Harris, USA, and changed the name to Alpex Pharma
2007 Capital increase and entrance of BB Biotech fund in the Alpex’s capital.